Brings total to twelve granted patents across the Company’s full portfolio.
Further Composition of Matter protection for SPL028.
U.S. Patent Grant To Strengthen Small Pharma’s Dmt Patent Strategy With Injectable Formulation.
Progress continues with multiple trials expected to enter clinic later this year.
Small Pharma reports highlights for the fiscal year ended February 2022.
Small Pharma shares business update ahead of annual financial results, including a new COO appointment.
Small Pharma expands its commercial portfolio with progress of two new trials.
European Patent Grant Strengthens Small Pharma’s Ketamine-based Patent Portfolio For The Treatment Of Depressive Disorders
Patent grant strengthens Small Pharma's portfolio for treatment for depressive disorders.
Small Pharma provides update to patent portfolio including receipt of an in order for grant notice for its patent related to psychedelic tryptamines
Small Pharma announces update on its patent portfolio since its filing statement on April 23,…